Correlation between Hepatitis B Virus and Microvascular Invasion in Hepatocellular Carcinoma

Fan CAO; Yang-wen LIU; Lei WEI; Nan XIE; Yi-jian YANG; Cheng QIAN; Chun-mang LI; Bi-mang FU; Jiang-pin XU; Rong-ji YAN; Wang ZENG

doi:10.12259/j.issn.2095-610X.S20210331

Volume 42 Issue 3

Apr. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2021 > 42(3): 127-134

Fan CAO, Yang-wen LIU, Lei WEI, Nan XIE, Yi-jian YANG, Cheng QIAN, Chun-mang LI, Bi-mang FU, Jiang-pin XU, Rong-ji YAN, Wang ZENG. Correlation between Hepatitis B Virus and Microvascular Invasion in Hepatocellular Carcinoma[J]. Journal of Kunming Medical University, 2021, 42(3): 127-134. doi: 10.12259/j.issn.2095-610X.S20210331

Citation:

Fan CAO, Yang-wen LIU, Lei WEI, Nan XIE, Yi-jian YANG, Cheng QIAN, Chun-mang LI, Bi-mang FU, Jiang-pin XU, Rong-ji YAN, Wang ZENG. Correlation between Hepatitis B Virus and Microvascular Invasion in Hepatocellular Carcinoma[J]. Journal of Kunming Medical University, 2021, 42(3): 127-134. doi: 10.12259/j.issn.2095-610X.S20210331

Citation:

Fan CAO, Yang-wen LIU, Lei WEI, Nan XIE, Yi-jian YANG, Cheng QIAN, Chun-mang LI, Bi-mang FU, Jiang-pin XU, Rong-ji YAN, Wang ZENG. Correlation between Hepatitis B Virus and Microvascular Invasion in Hepatocellular Carcinoma[J]. Journal of Kunming Medical University, 2021, 42(3): 127-134. doi: 10.12259/j.issn.2095-610X.S20210331

PDF( 678 KB)

Correlation between Hepatitis B Virus and Microvascular Invasion in Hepatocellular Carcinoma

doi: 10.12259/j.issn.2095-610X.S20210331

1.
Hepatobiliary and Pancreas Disease Area，The Second Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650101
2.
The First Ward of Surgery，Zhaotong Traditional Chinese Medicine Hospital，Zhaotong Yunnan 657009
3.
Dept. Of General Surgery，Yunnan Boya Hospital，Kunming Yunnan 650228，China

Received Date: 2020-12-09
Publish Date: 2021-03-25

Abstract

Abstract

Objective To explore the correlation between hepatitis B virus （HBV） infection and antiviral therapy and the formation and development of microvascular invasion （MVI） for hepatocellular carcinoma （HCC）. Methods Retrospective analysis was made on the clinical and pathological data of hepatocellular carcinoma patients undergoing radical hepatectomy in the Second Affiliated Hospital of Kunming Medical University from March 2016 to October 2018. Results The formation of MVI was related to preoperative antiviral therapy, HBVDNA quantification, AFP quantification and postoperative histopathological grading.Among hbV-associated HCC patients, multivariate Logistic regression analysis showed that antiviral therapy （OR = 0.44 p = 0.002）, HBVDNA quantification ≥2×10⁴～≤2×10⁷ IU/mL （OR = 2.79 p = 0.036）, and AFP quantification ≥400～≤1 000 ng/mL （OR = 0.31 p = 0.023） were independent risk factors for MVI, and antiviral therapy for more than half a year was independent protective factor for MVI. High levels of HBVDNA quantification （> 2×10⁴ IU/mL） may indicate high differentiation of MVI （P < 0.05）. In addition, significant HBVDNA quantification ≥2×10 ⁴～≤2×10⁷ IU/mL （AUC = 0.885 P < 0.001） may be of high diagnostic value in predicting the occurrence of MVI for HBV-associated HCC. Conclusion HBV infection and HBVDNA quantification levels are important factors in the formation of MVI in hepatocellular carcinoma. Antiviral therapy may have a preventive effect on the formation of MVI.A high level of HBVDNA quantification may indicate highly differentiated MVI. In addition, meaningful HBVDNA quantification is of certain value for THE occurrence of MVI in HBV-associated HCC.
- Hepatocellular carcinoma,
- Hepatitis B virus,
- Microvascular invasion

FullText(HTML)

References(33)

References

[1]	Sherman M,Kim R W,Dziura J. Risk scores for hepatocellular carcinoma in chronic hepatitis B[J]. Hepatology,2015,61(6):1784-1786. doi: 10.1002/hep.27765
[2]	Tarao K,Ohkawa S,Miyagi Y,et al. Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated liver cirrhosis[J]. Scandinavian Journal of Gastroenterology,2013,48(6):729-735. doi: 10.3109/00365521.2013.782064
[3]	Hanto D W,Curry M P,Sun M,et al. Hepatocellular Carcinoma (HCC) in a Patient With Hepatitis B Virus (HBV) Infection[J]. American Journal of Transplantation,2012,12(3):786-788. doi: 10.1111/j.1600-6143.2012.03979.x
[4]	European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection [published correction appears in J Hepatol. 2013 Jan;58（1）: 201. Janssen, Harry [corrected to Janssen, Harry L A]. J Hepatol, 2012, 57（1）: 167-185.
[5]	Cleary S P,Jeck W R,Zhao X,et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing[J]. Hepatology,2013,58(5):1693-1702.
[6]	中华预防医学会肿瘤预防与控制专业委员会感染相关肿瘤防控学组. 中国肝癌一级预防专家共识(2018)[J]. 中华预防医学杂志,2019,53(1):36-44.
[7]	Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015, 65（2）: 87-108.
[8]	Chen W,Zheng R,Baade P D,et al. Cancer statistics in China,2015[J]. CA:A Cancer Journal for Clinicians,2016,66(2):115-132. doi: 10.3322/caac.21338
[9]	何旭昶,安文慧,曾庆彬,等. 微血管侵犯分级对肝细胞癌行根治性肝切除术后早期复发的预测价值[J]. 临床肝胆病杂志,2020,36(8):1757-1762. doi: 10.3969/j.issn.1001-5256.2020.08.016
[10]	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 传染病信息,2020,33(6):481-500. doi: 10.3969/j.issn.1007-8134.2020.06.001
[11]	Li X,et al. Postoperative α-fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma:A propensity score matching analysis[J]. Surgery,2019,165(6):1161-1167.
[12]	Rodríguez-Perálvarez M,Luong T V,Andreana L,et al. A systematic review of microvascular invasion in hepatocellular carcinoma:diagnostic and prognostic variability[J]. Annals of Surgical Oncology,2013,20(1):325-339. doi: 10.1245/s10434-012-2513-1
[13]	吴孟超,汤钊猷,刘彤华,等. 原发性肝癌规范化病理诊断指南(2015年版)[J]. 临床肝胆病杂志,2015,31(6):833-839. doi: 10.3969/j.issn.1001-5256.2015.06.004
[14]	Zhang X,Patil D,Odze R D,et al. The microscopic anatomy of the esophagus including the individual layers,specialized tissues,and unique components and their responses to injury[J]. Ann N Y Acad Sci,2018,1434(1):304-318.
[15]	Takayama T,Makuuchi M,Hirohashi S,et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure[J]. Hepatology,1998,28(5):1241-1246. doi: 10.1002/hep.510280511
[16]	Yamamoto J,Kosuge T,Takayama T,et al. Recurrence of hepatocellular carcinoma after surgery[J]. British Journal of Surgery,1996,83(9):1219-1222.
[17]	Llovet J M,Burroughs A,Bruix J. Hepatocellular carcinoma[J]. The Lancet,2003,362(9399):1907-1917. doi: 10.1016/S0140-6736(03)14964-1
[18]	Matsumata T,Kanematsu T,Takenaka K,et al. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma[J]. Hepatology,1989,9(3):457-460. doi: 10.1002/hep.1840090320
[19]	Liu J,Zhu Q,Li Y,et al. Microvascular invasion and positive HB e antigen are associated with poorer survival after hepatectomy of early hepatocellular carcinoma:A retrospective cohort study[J]. Clinics and Research in Hepatology and Gastroenterology,2018,42(4):330-338. doi: 10.1016/j.clinre.2018.02.003
[20]	Kondo K,Chijiiwa K,Makino I,et al. Risk factors for early death after liver resection in patients with solitary hepatocellular carcinoma[J]. Journal of Hepato-Biliary-Pancreatic Surgery,2005,12(5):399-404. doi: 10.1007/s00534-005-1009-9
[21]	中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)摘要[J]. 中华肝脏病杂志,2012,20(6):419-426.
[22]	Koike K,Tsutsumi T,Fujie H,et al. Molecular Mechanism of Viral Hepatocarcinogenesis[J]. Oncology,2002,62(Suppl. 1):29-37. doi: 10.1159/000048273
[23]	Bosetti C,Turati F,La Vecchia C. Hepatocellular carcinoma epidemiology[J]. Best Practice & Research Clinical Gastroenterology,2014,28(5):753-770.
[24]	杨俊杰,鄢业鸿. 抗病毒治疗对HBV相关性HCC影响的研究进展[J]. 广东医学,2019,40(24):3489-3493.
[25]	Cheng Z,Yang P,Qu S,et al. Risk factors and management for early and late intrahepatic recurrence of solitary hepatocellular carcinoma after curative resection[J]. HPB,2015,17(5):422-427. doi: 10.1111/hpb.12367
[26]	Imamura H,Matsuyama Y,Tanaka E,et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy[J]. Journal of Hepatology,2003,38(2):200-207. doi: 10.1016/S0168-8278(02)00360-4
[27]	Sohn W,Paik Y,Kim J M,et al. HBV DNA and HBsAg Levels as Risk Predictors of Early and Late Recurrence after Curative Resection of HBV-related Hepatocellular Carcinoma[J]. Annals of Surgical Oncology,2014,21(7):2429-2435. doi: 10.1245/s10434-014-3621-x
[28]	Moon W S,Chang K,Tarnawski A S. Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma:relationship to vascular invasion and estrogen receptor[J]. Human Pathology,2004,35(4):424-429. doi: 10.1016/j.humpath.2003.11.007
[29]	Xu J,Liu H,Chen L,et al. Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21-activated kinase 1[J]. Gastroenterology,2012,143(1):199-212. doi: 10.1053/j.gastro.2012.03.053
[30]	Chong C C N. Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma[J]. World Journal of Gastroenterology,2014,20(20):6006. doi: 10.3748/wjg.v20.i20.6006
[31]	Kubo S. Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma[J]. World Journal of Gastroenterology,2015,21(27):8249. doi: 10.3748/wjg.v21.i27.8249
[32]	曲超,刘奎,王一休,等. 乙型肝炎病毒感染及抗病毒治疗对肝细胞癌微血管侵犯的影响[J]. 中国普通外科杂志,2019,28(1):10-17. doi: 10.7659/j.issn.1005-6947.2019.01.002
[33]	王贵强,王福生,成军,等. 慢性乙型肝炎防治指南(2015年版)[J]. 中华实验和临床感染病杂志(电子版),2015,19(5):1-18.

Relative Articles(20)

Relative Articles

[1]	Xiaoyan WANG, Ya LI, Chenglu HE, Lin WANG, Zhiqiang MA, Xinrui WAN. Study on Immune Function and Drug Resistance of Tuberculosis Patients Co-infected with HBV，HCV and HIV in Yunnan. Journal of Kunming Medical University, 2023, 44(12): 51-58. doi: 10.12259/j.issn.2095-610X.S20231209
[2]	Dong PU, Tingting YU, Lihua LI, Runwu ZHANG, Kunli WU, Dongling LI. Analysis of Serum High-sensitivity HBV DNA in Patients with Chronic Hepatitis B with Low Viral Load in Kunming Area. Journal of Kunming Medical University, 2023, 44(1): 116-121. doi: 10.12259/j.issn.2095-610X.S20230114
[3]	Yixuan CHEN, Lin WANG, Xiuhong XIA, Zaikun PENG, Yi DING, Runjiao SHI, Xuefen LEI. Research Progress on the Mechanisms of Autophagy in Hepatocellular Carcinoma. Journal of Kunming Medical University, 2023, 44(4): 159-164. doi: 10.12259/j.issn.2095-610X.S20230416
[4]	Ming ZHANG, Chenglong YU, Jinpeng CAO. ZNF384 Regulates Metastasis of Hepatocellular Carcinoma via GCLM. Journal of Kunming Medical University, 2023, 44(11): 56-62. doi: 10.12259/j.issn.2095-610X.S20231108
[5]	Xiaojie CHEN, Xingrao WU, Shuhui YU, Zheng LI, Lan ZHANG. Advances on HBV Infection in the Occurrence and Development of Gynecologic Malignancies. Journal of Kunming Medical University, 2022, 43(4): 152-157. doi: 10.12259/j.issn.2095-610X.S20220424
[6]	Tianhong ZHANG, Hongju YANG. Research Progress of Exosomal miRNA in Hepatocellular Carcinoma. Journal of Kunming Medical University, 2022, 43(2): 150-153. doi: 10.12259/j.issn.2095-610X.S20220221
[7]	Haiyan FU, Junfang YAN, Hongjuan LI, Lin WANG, Jie ZHANG, Yujun ZHOU, Bin XU, Yu LUO. Effect of Time Interval on the Outcome with Transarterial Chemoembolization Followed Microwave Ablation with Hepatocellular Carcinoma. Journal of Kunming Medical University, 2022, 43(11): 63-70. doi: 10.12259/j.issn.2095-610X.S20221127
[8]	Song-qin LV, Xi-ruo SUN, Shan HUANG, Li-ping XV, Juan ZHANG, Yi-na WANG, Xiao-fei LI, Yong-rui YANG. The Application Value of Dry Fluorescent Luminescence in The Diagnosis and Treatment of HBV Infection. Journal of Kunming Medical University, 2021, 42(8): 65-70. doi: 10.12259/j.issn.2095-610X.S20210812
[9]	Xu Hai Xia , Li Xin Hong . . Journal of Kunming Medical University, 2020, 41(06): 132-135.
[10]	Li-xian YUAN, Hong-tao ZHANG, Rui LI, Kun-rui CHEN, Kun-qian CHEN, An-shu XU. Diagnostic Efficacy of Serum PIVKA-Ⅱ Detection in Primary Hepatocellular Carcinoma. Journal of Kunming Medical University, 2020, 41(12): 80-84. doi: 10.12259/j.issn.2095-610X.S20201223
[11]	Pu Dong , Li Xiao Fei , Yu Ting Ting , Wang Hong Ying , Zhang Run Wu , Li Li Hua , Bai Jing , Ding Cai Mei , Li Dong Ling , Yang Yong Rui . . Journal of Kunming Medical University, 2020, 41(06): 149-155.
[12]	Tan Hua , Ren Hong , Zhao Ling , You Ding Yun , Yang Ya Chen . Prognostic Factors of Patients with Primary Hepatocellular Carcinoma Treated with TACE. Journal of Kunming Medical University, 2019, 40(03): 29-34.
[13]	Pu Dong , Yu Ting Ting , Wang Hong Ying , Li Li Hua , Zhang Run Wu , Ding Cai Mei , Bai Jing , Li Dong Ling , Li Xiao Fei . . Journal of Kunming Medical University, 2019, 40(11): 131-135.
[14]	Lei Xi Feng , Hou Feng Qiang , Liu Tao , Zhang Wei . . Journal of Kunming Medical University, 2018, 39(11): 11-15.
[15]	Tian Bo Yan , Yang Qin Ling , Zhang Jiao Qiong , Han Na , Liu Shao Hua . The Curative Effect of Auxiliary Hepatic Arterial Chemoembolization in the Treatment of Microvascular Invasion of Hepatocellular Carcinoma. Journal of Kunming Medical University, 2018, 39(08): 86-92.
[16]	Lei Xi Feng , Hou Feng Qiang , Yang Shao Hua , Zhang Wei . . Journal of Kunming Medical University, 2018, 39(12): 49-53.
[17]	Li Yong Gang . Vertical Transmission of Hepatitis B Virus in Human Early Embryos. Journal of Kunming Medical University,
[18]	Qiu Jian Wu . . Journal of Kunming Medical University,
[19]	Su Ying . . Journal of Kunming Medical University,
[20]	Yu Jie . . Journal of Kunming Medical University,